Clinical Trials Browser

Phase 2 × pazopanib × Sarcoma × Clear all

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT05679921 2025-07-16

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Phase 2 Recruiting

Sarcoma

NCT06816771 2025-02-10

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Phase 2 Recruiting

Recurrence, Rhabdomyosarcoma

NCT02203760 2024-11-15

PazoDoble

Phase 2 Active not recruiting

Carcinosarcoma, Leiomyosarcoma, Recurrence

NCT02207309 2024-08-09

Pazopanib Maintenance Phase II

Phase 2 Terminated

1 enrolled 4 charts

Sarcoma

NCT03798106 2023-06-12

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Phase 2 Completed

Sarcoma

NCT02066285 2023-03-27

Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

Phase 2 Completed

Chondrosarcoma, Extraskeletal Myxoid, Neoplasm Metastasis, Solitary Fibrous Tumors

NCT01330966 2023-03-10

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Phase 2 Completed

47 enrolled 10 charts

Chondrosarcoma

NCT01462630 2022-08-19

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase 2 Completed

29 enrolled 10 charts

Hemangiosarcoma, Sarcoma

NCT02357810 2022-06-07

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Phase 2 Completed

178 enrolled 16 charts

Liposarcoma, Sarcoma, Osteosarcoma

NCT02212015 2022-03-22

EVA

Phase 2 Terminated

26 enrolled 16 charts

Hemangiosarcoma

NCT01532687 2021-09-27

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Phase 2 Completed

54 enrolled 12 charts

Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT01759303 2021-04-13

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

Phase 2 Terminated

Osteosarcoma

NCT01543802 2021-01-26

NOPASS

Phase 2 Terminated

Sarcoma

NCT01956669 2020-08-12

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Phase 2 Completed

57 enrolled 22 charts

Sarcoma

NCT02300545 2020-08-05

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Phase 2 Completed

56 enrolled 11 charts

Sarcoma

NCT01692496 2020-07-23

Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial

Phase 2 Completed

52 enrolled 14 charts

Liposarcoma, Neoplasm Metastasis

NCT01593748 2020-04-06

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Phase 2 Completed

90 enrolled 12 charts

Sarcoma

NCT01392352 2020-02-13

HYPAZ

Phase 2 Terminated

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT01442662 2020-01-31

LMS03

Phase 2 Completed

Leiomyosarcoma, Neoplasm Metastasis

NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase 2 Completed

22 enrolled 8 charts

GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT02575066 2019-06-27

PASART-2

Phase 2 Terminated

Sarcoma

NCT02113826 2017-11-06

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Phase 2 Terminated

Sarcoma, Alveolar Soft Part

NCT02342600 2017-10-12

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Phase 2 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03149120 2017-08-22

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Phase 2 Withdrawn

Neoplasm Metastasis, Sarcoma

NCT01861951 2017-08-21

EPAZ

Phase 2 Completed

Sarcoma

NCT01524848 2017-05-10

PAGIST

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01391611 2017-04-07

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Phase 2 Terminated

25 enrolled 7 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00459381 2017-03-15

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed

35 enrolled 12 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01506596 2017-02-15

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Phase 2 Completed

42 enrolled 9 charts

Liposarcoma

NCT02367651 2016-10-12

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

Phase 2 Withdrawn

Sarcoma

NCT01059656 2016-07-01

DFSP-PAZO

Phase 2 Terminated

Dermatofibrosarcoma

NCT01323400 2016-02-25

PAZOGIST

Phase 2 Completed

GIST

NCT00297258 2016-02-03

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Phase 2 Completed

148 enrolled 8 charts

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial